We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Wide-Range, Automated Dabigatran Assay Launched

By LabMedica International staff writers
Posted on 18 Nov 2015
A new assay kit for dabigatran (Pradaxa) measurement in blood plasma provides automation, higher specificity, and broader working range (currently for research use only).

Diagnostica Stago, Inc., the US subsidiary of hemostasis leader Diagnostica Stago, S.A.S. More...
France (Asnières sur Seine, France), expands its offering for direct measurement of oral anticoagulants (DOACs) with the launch of STA-ECA-II—a next-generation ecarin-based chromogenic assay for dabigatran (Pradaxa). With this addition, Stago offers the only complete portfolio of assays for measurement of DOACs. Automated with barcoded loading on Stago’s high-throughput analyzers, STA-ECA-II enables laboratories an efficient and standardized approach to measure dabigatran in plasma samples.

STA-ECA-II is a highly-specific tool for directly measuring dabigatran (Pradaxa) concentration in plasma and is insensitive to lupus anticoagulants and heparin along with coagulation factor and fibrinogen levels. With a wide working range of 15–460 ng/mL and 28-day stability at 2–8 °C, the kit is flexible for a variety of sample testing requirements.

Compared to liquid chromatography-mass spectrometry (LC-MS)-based methods, STA-ECA-II demonstrates excellent correlation for measurement of total dabigatran concentrations. It provides confidence in results across the entire measurement range, with an advantage over other methods, especially for samples with low concentrations.

The STA-ECA-II kit (catalog number 01108), along with the STA-Dabigatran Calibrator (catalog number 01109) and STA-Dabigatran Control (catalog number 01110) products are labeled for research-use-only in the United States and Canada, and are not for use in diagnostic procedures.

Related Links:

Diagnostica Stago 
Diagnostica Stago, US 



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Hematology Consumables
Bioblood Devices
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.